Physician
Inland Hematology-Oncology Medical Group INC
Inland Hematology-Oncology Medical Group INC was paid $5.54M by Medicaid between Jan 2018 and Nov 2024, across 45 billing codes. Its largest line is 99214, doctor's office visit, returning patient (more involved) — 37% of everything it billed.
33Billing provider infoINLAND HEMATOLOGY-ONCOLOGY MEDICAL GROUP INC
SAN BERNARDINO, CA 92404
SAN BERNARDINO, CA 92404
33aNPI1467437848assigned 12/08/2005
33bProvider typeHematology & Oncology Physician
28Total paid$5.54M
24GClaims149,168
24DCodes billed45
24AFirst – last monthJan 2018 – Nov 2024
Compared with peers
Next to other Hematology & Oncology Physician providers in California
Rank by total paid#4 of 180
Median peer was paid$26K
This provider vs. median216×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 21,052 | $627K | |
| 2019 | 22,433 | $746K | |
| 2020 | 18,096 | $590K | |
| 2021 | 18,192 | $686K | |
| 2022 | 22,022 | $931K | |
| 2023 | 28,118 | $1.07M | |
| 2024incomplete | 19,255 | $891K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 37% | 30,390 | 23,947 | $2.06M |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 16% | 15,956 | 10,710 | $894K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | 12% | 10,421 | 6,202 | $682K |
| 96367 | 8.2% | 10,669 | 6,775 | $456K | |
| 96417 | 6.4% | 4,937 | 2,827 | $356K | |
| 36000 | 3.6% | 7,382 | 5,090 | $200K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 2.3% | 20,274 | 15,116 | $127K |
| Q5106 | Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units | 2.1% | 548 | 359 | $118K |
| 99204 | Doctor's office visit, new patient (more involved)Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity | 2.1% | 853 | 853 | $118K |
| 99070 | 2.0% | 11,458 | 7,706 | $109K | |
| J1756 | Injection, iron sucrose, 1 mg | <1% | 2,054 | 1,685 | $55K |
| 99205 | Prolong outpt/office vis | <1% | 419 | 419 | $49K |
33 more codes
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 3,398 | $46K |
| J0885 | Injection, epoetin alfa, (for non-esrd use), 1000 units | <1% | 210 | $44K |
| 99232 | Hospital visit by a doctor, follow-up day | <1% | 980 | $40K |
| Q5107 | Injection, bevacizumab-awwb, biosimilar, (mvasi), 10 mg | <1% | 15 | $28K |
| 96415 | <1% | 969 | $25K | |
| J1626 | Injection, granisetron hydrochloride, 100 mcg | <1% | 8,732 | $23K |
| J0897 | Injection, denosumab, 1 mg | <1% | 14 | $20K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 967 | $16K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 8,362 | $15K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 281 | $12K |
| J1750 | Injection, iron dextran, 50 mg | <1% | 184 | $12K |
| 99223 | Prolong inpt eval add15 m | <1% | 101 | $9K |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 64 | $7K |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 5,267 | $4K |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 1,274 | $3K |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 26 | $3K |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 60 | $2K |
| 96523 | <1% | 89 | $2K | |
| J9190 | Injection, fluorouracil, 500 mg | <1% | 469 | $2K |
| J0640 | Injection, leucovorin calcium, per 50 mg | <1% | 263 | $869.80 |
| J9263 | Injection, oxaliplatin, 0.5 mg | <1% | 49 | $856.06 |
| J9267 | Injection, paclitaxel, 1 mg | <1% | 59 | $584.02 |
| J2469 | Injection, palonosetron hcl, 25 mcg | <1% | 46 | $508.13 |
| J9045 | Injection, carboplatin, 50 mg | <1% | 56 | $358.98 |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 1,402 | $293.70 |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 20 | $218.29 |
| J2916 | Injection, sodium ferric gluconate complex in sucrose injection, 12.5 mg | <1% | 15 | $192.48 |
| J9060 | Injection, cisplatin, powder or solution, 10 mg | <1% | 27 | $164.27 |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | <1% | 136 | $146.43 |
| 36415 | Collection of venous blood by venipuncture | <1% | 188 | $86.05 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 32 | $39.60 |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 26 | $29.02 |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 26 | $14.70 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialMALIK, RAJIV (OWNER)